Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma

被引：4
|
作者：
Gray, Steven G. [1 ]
Meirson, Tomer [2 ]
Mutti, Luciano [3 ,4 ]
机构：
[1] St James Hosp, Trinity St Jamess Canc Inst, Thorac Oncol Res Grp, Dublin, Ireland
[2] Beilinson Med Ctr, Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[3] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Coppito Bldg,Second Floor Via Vetorio SNC, I-67100 Laquila, Italy
[4] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Hlth Res Org, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 04期
关键词：
MALIGNANT PLEURAL MESOTHELIOMA; THORACIC ONCOLOGY PLATFORM; CHEMOTHERAPY; PEMBROLIZUMAB;
D O I：
10.1016/j.jtho.2024.01.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：541 / 546
页数：6
相关论文
共 50 条
  • [31] Real-world outcomes and molecular correlates of incorporating immunotherapy (IO) and bevacizumab (Bev) in treating patients with peritoneal mesothelioma (PeM): A comparative analysis with pleural mesothelioma (PM)
    Huey, Ryan W.
    Gandhi, Nishant
    Helmink, Beth A.
    Overman, Michael J.
    Malpica, Anais
    Estrella, Jeannelyn
    Taggart, Melissa
    Allam, Joelle
    Scally, Christopher
    Mansfield, Paul F.
    Matamoros, Aurelio
    Elliott, Andrew
    VanderWalde, Ari
    Ma, Patrick C.
    Halmos, Balazs
    Liu, Stephen V.
    Fournier, Keith F.
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Characteristics of patients treated for CLL in a real-world registry: results from informCLL™
    Mato, Anthony
    Sharman, Jeff
    Pagel, John
    Brander, Danielle
    Kadish, Karen
    Tomlinson, Brian
    Ipe, David
    Yang, Huiying
    Arango-Hisijara, Israel
    Srivastava, Bhavini
    Schenkel, Brad
    Barrientos, Jacqueline
    LEUKEMIA & LYMPHOMA, 2017, 58 : 48 - 49
  • [33] Predictors of mortality in CRT patients: results from a large real-world population
    Botto, G. L.
    Palmisano, P.
    Pepi, P.
    D'Onofrio, A.
    Marini, M.
    De Simone, A.
    Caico, S. I.
    Pecora, D.
    Santamaria, M.
    Arena, G.
    Pieragnoli, P.
    Savarese, G.
    Bertaglia, E.
    Malacrida, M.
    Stabile, G.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1170 - 1170
  • [34] The real-world impact of cancer immunotherapy on the survival of patients with metastatic melanoma
    Donia, M.
    Ellebaek, E.
    Oellegaard, T. H.
    Duval, L.
    Aaby, J. B.
    Hoejberg, L.
    Koehler, U. H.
    Schmidt, H.
    Bastholt, L.
    Svane, I-M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers
    Mullins, C. Daniel
    VALUE IN HEALTH, 2019, 22 (07) : 751 - 753
  • [36] Real-world outcomes of pembrolizumab in peritoneal mesothelioma.
    Marmarelis, Melina Elpi
    Wang, Xiao
    Roshkovan, Leonid
    Walker, Suzanne
    McNulty, Sally
    Ciunci, Christine Agnes
    Muira, John
    Katz, Sharyn, I
    Cengel, Keith A.
    Karakousis, Giorgos
    Langer, Corey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] From real-world electronic health record data to real-world results using artificial intelligence
    Knevel, Rachel
    Liao, Katherine P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03) : 306 - 311
  • [38] Real-World Use of Immunotherapy for Hepatocellular Carcinoma
    Sara, Amir
    Ruff, Samantha M.
    Noonan, Anne M.
    Pawlik, Timothy M.
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2023, 14 : 63 - 74
  • [39] ANTIBIOTICS AND RESPONSE TO IMMUNOTHERAPY: REAL-WORLD EXPERIENCE
    Ahmed, Yasar
    Calvert, Paula
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A435 - A436
  • [40] A Real-world Experience With Tezepelumab as the First Biologic Option in Severe Asthma Patients
    Mohan, A.
    Bagheri, A.
    Senn, R.
    Harwood, H.
    Fergan, J.
    Derstine, B.
    Lugogo, N. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
12345